Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.76 |
| ▸ | NPC1 | O15118 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911628 | 0.87 | LMNA (0.77) | LMNAALDH1A1SMN1; SMN2CYP2C9ATM | |
| SCHEMBL11536910 | 0.86 | ALDH1A1 (1.00) | LMNAALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL4709068 | 0.85 | LMNA (0.74) | LMNAALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL2981180 | 0.85 | ALDH1A1 (0.97) | LMNAALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL26313603 | 0.85 | ALDH1A1 (0.97) | LMNAALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL19602435 | 0.83 | GLA (0.76) | LMNAALDH1A1SMN1; SMN2CYP2C9ATM | |
| SCHEMBL16219388 | 0.83 | LMNA (0.70) | LMNAALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL3847472 | 0.82 | ALDH1A1 (0.97) | LMNAALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL334552 | 0.82 | ALDH1A1 (0.73) | LMNAALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL1812032 | 0.82 | ALDH1A1 (0.73) | LMNAALDH1A1SMN1; SMN2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20210147478-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-2019202052-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201432-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | WO | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| WO-2018122419-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
| EP-3342779-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2018-07-04 | — | — | EP | disclosed |
| EP-1349841-B1 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-7173129-B2 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHERO GENICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2004084901-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | LMNA 2762/4885ALDH1A1 1653/4885SMN1; SMN2 1575/4885 |
| US-20210147478-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | TFPI, F11, F13B | LMNA 1300/4885ALDH1A1 2881/4885SMN1; SMN2 3773/4885 |
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | LMNA 2762/4885ALDH1A1 1653/4885SMN1; SMN2 1575/4885 |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | LMNA 2426/4885ALDH1A1 1469/4885SMN1; SMN2 3418/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | LMNA 2426/4885ALDH1A1 1469/4885SMN1; SMN2 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.